Marion McCourt, Executive Vice President Commercial of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), filed a Form 4 on November 18, 2026, disclosing the sale of 566 shares of common stock on November 16, 2026, under a Rule 10b5-1 trading plan.
Key Highlights
- Reporting person: Marion McCourt, EVP Commercial at Regeneron Pharmaceuticals, Inc.
- Total shares sold: 566 shares of common stock disposed of on November 16, 2026, across 13 separate transactions.
- Price range: Sales occurred at volume-weighted average prices ranging from $952.79 to $971.93 per share.
- Post-transaction direct ownership: 10,305 shares of common stock held directly following the reported sales.
- Indirect holdings: 219 shares held indirectly through a 401(k) Plan, unchanged by the transactions.
- 10b5-1 plan: All dispositions were made pursuant to a plan adopted on February 17, 2026, intended to comply with Rule 10b5-1(c).
McCourt's November 16 Sales Across 13 Tranches at Prices Up to $971.93
According to the Form 4 filed with the SEC on November 18, 2026, Marion McCourt, identified in the filing as EVP Commercial of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), disposed of a total of 566 shares of common stock on November 16, 2026. The sales were executed in 13 separate tranches, each at a distinct volume-weighted average price, with individual tranche sizes ranging from 21 to 66 shares.
The filing discloses that prices across the tranches ranged from a low of $952.79 per share (for a sale of 44 shares, with actual prices between $952.64 and $952.89) to a high of $971.93 per share (for a sale of 26 shares). Several tranches include footnotes noting that the stated price represents a volume-weighted average and that full detail on individual prices within each tranche will be provided upon request by the Commission staff, the company, or a security holder. All dispositions, according to the filing, were "made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 17, 2026."
Following the reported transactions, the filing states that McCourt directly holds 10,305 shares of Regeneron common stock. In addition, 219 shares are reported as indirectly held through a 401(k) Plan; no transactions were reported with respect to those indirectly held shares. The filing was signed by Marion McCourt and dated November 18, 2026.
What Was Disclosed
Marion McCourt, EVP Commercial of Regeneron Pharmaceuticals, disclosed the sale of 566 common shares on November 16, 2026, under a pre-established 10b5-1 plan, with direct beneficial ownership of 10,305 shares remaining after the transactions.





Please wait processing your request...